Literature DB >> 19748217

Femoral artery complications after cardiac catheterization: a study of patient profile.

Mario Castillo-Sang1, Albert W Tsang, Babatunde Almaroof, James Cireddu, Joseph Sferra, Gerald B Zelenock, Milo Engoren, Gregory Kasper.   

Abstract

BACKGROUND: Femoral artery complications after cardiac catheterization range from simple events to severe complications requiring invasive techniques or surgery with significant economic costs. This study evaluated early femoral arterial complications from percutaneous arterial access during diagnostic and interventional cardiac catheterizations in an era of widespread use of closure devices and intense anticoagulation.
METHODS: Patients undergoing percutaneous cardiac catheterization via the femoral artery between August 2005 and December 2005 were identified using an ICD-9 patient database. Forty-six data points were extracted by retrospective chart review, including demographics, comorbidities, type of anticoagulation, procedural details, and postprocedural complications. Univariable analysis and binary logistic regression were used to determine factors associated with complications.
RESULTS: Eighty-two of 579 patients (14%) suffered complications. The most common complications were hematomas (51 patients, 10%) and active bleeding (14 patients, 2.4%). Closure devices were used in 470 patients. After multivariable correction, use of preprocedural (odds ratio [OR]=5.65, 95% confidence interval [CI] 2.58-12.3, p<0.001) and intraprocedural (OR=4.88, 95% CI 1.95-12.3, p<0.001) antithrombotic agents (antiplatelet and/or anticoagulants), intraprocedural clopidogrel (OR=2.98, 95% CI 1.21-7.30, p=0.017), and postprocedural heparin (OR=29.4, 95% CI 3.56-250, p=0.002) were associated with increased risk. Coronary artery disease was associated with increased risk (OR=11.1, 95% CI 4.78-25.6, p<0.001), while use of a closure device (OR=0.263, 95% CI 0.125-0.553, p<0.001), male gender (OR=0.421, 95% CI 0.220-0.805, p=0.009), and prior catheterization (OR=0.033, 95% CI 0.012-0.095, p<0.001) were protective.
CONCLUSION: With increasing numbers of complex coronary endovascular procedures and widespread use of high-dose multidrug antithrombotic therapy, femoral artery injuries will continue to be a significant risk for patients. Postprocedural monitoring with a high level of suspicion and use of vascular closure devices in high-risk patients may decrease the incidence of femoral artery complications. The use of vascular closure devices after low-risk procedures in male patients or those with previous ipsilateral catheterization might not be warranted but needs further study. Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748217     DOI: 10.1016/j.avsg.2009.06.025

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  8 in total

1.  Contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning.

Authors:  Jian-Ping Qin; Shan-Hong Tang; Ming-De Jiang; Qian-Wen He; Hong-Bin Chen; Xin Yao; Wei-Zheng Zeng; Ming Gu
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

2.  Routine use of fluoroscopic guidance and up-front femoral angiography results in reduced femoral complications in patients undergoing coronary angiographic procedures: an observational study using an Interrupted Time-Series analysis.

Authors:  Emily V Castle; Krishnaraj S Rathod; Oliver P Guttmann; Alice M Jenkins; Carmel D McCarthy; Charles J Knight; Constantinos O'Mahony; Anthony Mathur; Elliot J Smith; Roshan Weerackody; Adam D Timmis; Andrew Wragg; Daniel A Jones
Journal:  Heart Vessels       Date:  2018-09-27       Impact factor: 2.037

3.  Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation.

Authors:  Timir S Baman; Krit Jongnarangsin; Aman Chugh; Arisara Suwanagool; Aurelie Guiot; Arin Madenci; Spencer Walsh; Karl J Ilg; Sanjaya K Gupta; Rakesh Latchamsetty; Suveer Bagwe; James D Myles; Thomas Crawford; Eric Good; Frank Bogun; Frank Pelosi; Fred Morady; Hakan Oral
Journal:  J Cardiovasc Electrophysiol       Date:  2011-01-15

4.  Bed rest for preventing complications after transfemoral cardiac catheterisation: a protocol of systematic review and network meta-analysis.

Authors:  Alberto Dal Molin; Fabrizio Faggiano; Fabio Bertoncini; Giulia Buratti; Erica Busca; Roberta Casarotto; Samanta Gaboardi; Elias Allara
Journal:  Syst Rev       Date:  2015-04-15

5.  Groin complications in endovascular mechanical thrombectomy for acute ischemic stroke: a 10-year single center experience.

Authors:  Veer A Shah; Coleman O Martin; Angela M Hawkins; William E Holloway; Shilpa Junna; Naveed Akhtar
Journal:  J Neurointerv Surg       Date:  2015-05-22       Impact factor: 5.836

6.  Emergency Percutaneous Coronary Intervention Through the Left Radial Artery is Associated with Less Vascular Complications than Emergency Percutaneous Coronary Intervention Through the Femoral Artery.

Authors:  Guoqing Qi; Qi Sun; Yue Xia; Liye Wei
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

7.  Pituitrin use is associated with an increased risk of inguinal hematomas and pseudoaneurysms in patients undergoing femoral artery puncture.

Authors:  Fang Wang; Hua Su; Xiaoxia Wang; Qionghui Wu; Yong Zhou; Hangdi Xu; Ruifeng Zhang
Journal:  J Int Med Res       Date:  2019-05-23       Impact factor: 1.671

8.  Ultrasound-guided puncture reduces bleeding-associated complications, regardless of calcified plaque, after endovascular treatment of femoropopliteal lesions, especially using the antegrade procedure: A single-center study.

Authors:  Kentaro Fukuda; Shinya Okazaki; Masayuki Shiozaki; Iwao Okai; Akihisa Nishino; Hiroshi Tamura; Kenji Inoue; Masataka Sumiyoshi; Hiroyuki Daida; Tohru Minamino
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.